Latest Articlesddd

Gilead Sciences Could Acquire Immunomedics at $20 Billion. See Also: AstraZeneca Vaccine Trial Resumed

September 12, 2020 0

Gilead Sciences News Is Not Just Gossip Real news, not just gossip, is spreading today about …

Agenus Stock Rallied Yesterday

September 11, 2020 0

Why Agenus Stock Rallied Yesterday On September 2, 2020 we posted an article about Agenus (AGEN) …

From Inovio: Thermo Fisher Scientific Will Manufacture the Inovio COVID-19 Vaccine Candidate

September 9, 2020 0

Inovio COVID-19 Vaccine Candidate Will be Manufactured by Thermo Fisher Scientific Thermo Fisher Scientific (TMO) joins …

Compugen Has Encouraging News

September 8, 2020 0

Compugen Announced Encouraging News from Its Phase 1/2 Study of COM701 Compugen (CGEN) announced that the …

Sanofi and GlaxoSmithKLine COVID-19 Vaccines are Advancing in Clinical Trial

September 3, 2020 0

Sanofi and GlaxoSmithKline Have COVID-19 Vaccines Advancing in Clinical Trial Sanofi (SNY) and GlaxoSmithKline (GSK) started …

The U.S. CDC Tells the 50 States to Prepare for COVID-19 Vaccines by the End of October

September 3, 2020 0

CDC Is Asking States to Prepare for COVID-19 Vaccines The U.S. Center of Disease Control and …

Agenus: Could It Be a Resurrection? See Also: Prohost Performing Stocks

September 2, 2020 0

Agenus Announced Data from Phase 2 Trials of Balstilimab Agenus (AGEN) immuno-oncology company announced that data …

Moderna Inc Stock is Tanking After Rallying

September 1, 2020 0

Moderna Inc Late August Announcements  On August 28, 2020 Moderna Inc (MRNA) issued a press release …

Why The Time Has Come for Rhythm Pharmaceuticals to Outperform

August 28, 2020 0

Rhythm Pharmaceuticals Inc Rhythm Pharmaceuticals (RYTM) is a late-stage biopharmaceutical company with a product pipeline that …

Moderna Encouraging News. See Also: Translate Bio and Sanofi Good News

August 27, 2020 0

Moderna Presented Interim Clinical Data about mRNA-1273 for COVID-19 Moderna (MRNA) presented new Interim Clinical Data …

Exelixis Announces Submission of sNDA to U.S. FDA for Cabozantinib in Combination with Nivolumab for Advanced RCC

August 25, 2020 0

Exelixis Announces Submission of sNDA to US FDA for CABOMETYX® Exelixis (EXEL) announced the submission of …

Kazia Therapeutics Product Paxalisib Beats Temozolomide in Overall Survival in Mid-Phase Trial

August 25, 2020 0

The US FDA Awards Fast Track Designation to Paxalisib for Glioblastoma  Kazia Therapeutics Ltd (KZIA) – an …

What’s Going on with Gene Therapy?

August 25, 2020 0

Recent Gene Therapy News On August 20, 2020 Audentes Therapeutics, which was taken over by Astellas …

The FDA’s Complete Response Letters, Creating Investment Opportunities?

August 20, 2020 0

Yesterday, under Today’s Highlights, we posted that the U.S. FDA issued a Complete Response Letter (CRL) …

Gilead Sciences: An FDA Complete Response Letter Will Not Stop This Firm from Rallying

August 19, 2020 0

Gilead Sciences Was Issued a CLR from the FDA for Filgotinib Gilead Sciences (GILD) is in …

A Royal Reception by Investors for CureVac. See Also: Good Oncology News for Bristol-Myers Squibb

August 17, 2020 0

CureVac is Publicy Trading on the NASDAQ CureVac is now publicly trading on the NASDAQ stock …

An Important Announcement from Sorrento Therapeutics

August 13, 2020 0

Sorrento Therapeutics Announcement Sorrento Therapeutics (SRNE) announced that it believes it has uncovered fraudulent attempts to …

Monopar Therapeutics: A Plan for a Test that Predicts COVID-19 Patients Who Might Likely Develop Severe Respiratory Failure

August 13, 2020 0

A Predictive COVID-19 Test? COVID-19 infected people are not all affected to the same degree with …

Intellia Therapeutics: Realizing the Dream of Curing Devastating Diseases

August 11, 2020 0

Intellia Therapeutics  Reporting operational highlights and financial results for the second quarter ended June 30, 2020, Intellia …

Seres Therapeutics Oral Microbiome Product SER-109 Meets Trial Endpoint

August 10, 2020 0

Seres Therapeutics Oral Microbiome Product SER-109 for Recurrent C. Difficile Infection Meets Trial Endpoint SER-109 demonstrated …